Dr. Zeng is a T cell expert who has devoted over 20 years to studying the immunobiology of cancer/testis antigens and their clinical implications. Earlier in his career, Dr. Zeng completed his postdoctoral fellowship at the NCI with Dr. Steven A. Rosenberg where Dr. Zeng and his colleagues were the first to clone NY-ESO-1 using T cells. After joining UCLA faculty in 2002, his lab was the first to identify dendritic cell surface receptors for NY-ESO-1 and develop the “A+PSA” immunodiagnostic assay for prostate cancer. His work has resulted in 10 patents and more than 40 peer-reviewed publications as well as grant support from the Department of Defense, American Cancer Society and National Institutes of Health. Dr. Zeng is a recipient of the Certificate of Achievement from NCI, the Stein Oppenheimer award and Lab2Market award from UCLA. He obtained his PhD in Biochemistry from Virginia Tech and a BS in Biology from Peking University
Speaking In
[Available On-Demand]
T-Cure Bioscience, Inc. is an innovative immuno-oncology company committed to delivering effective…